SCHEMBL844527

SCHEMBL844527

CC(=N)NC(C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20315914 0.76 EPHX1 (0.36)
SCHEMBL1275944 0.74 MEN1 (0.44)
SCHEMBL12927056 0.69 MEN1 (0.40)
SCHEMBL8344601 0.69
SCHEMBL19041345 0.69 MEN1 (0.40)
SCHEMBL4105241 0.69
SCHEMBL14316706 0.67 MEN1 (0.33)
Iodide SCHEMBL5453631 0.67
Iodide SCHEMBL5458379 0.67
SCHEMBL4094792 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037447-B2 Systems and processes for polymer production NOVOMER, INC. (US) 2024-07-16 US disclosed
US-20230365563-A1 QUINAZOLINE COMPOUND AND APPLICATION THEREOF SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2023-11-16 US disclosed
US-20230219896-A1 CANNABINOID RECEPTOR MEDIATING COMPOUNDS THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-07-13 US disclosed
US-20230202983-A1 CANNABINOID RECEPTOR MEDIATING COMPOUNDS THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-06-29 US disclosed
US-11021444-B2 Antiviral compounds Janssen Biopharma, Inc. (US) 2021-06-01 US disclosed
WO-2020110009-A1 CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS NOVARTIS AG (CH) 2020-06-04 WO disclosed
WO-2020041417-A1 CYCLOALKYL-CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2020-02-27 WO disclosed
US-20190263754-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. (US) 2019-08-29 US disclosed
US-20180179242-A1 CATALYSTS AND METHODS FOR POLYMER SYNTHESIS NOVOMER, INC. 2018-06-28 US disclosed
US-20180057619-A1 SYSTEMS AND PROCESSES FOR POLYACRYLIC ACID PRODUCTION NOVOMER, INC. (US) 2018-03-01 US disclosed
EP-1927590-B1 METHOD FOR PRODUCING 1-SUBSTITUTED-5-ACYLIMIDAZOLE COMPOUND UBE INDUSTRIES (JP) 2011-07-20 EP disclosed
US-20110152497-A1 CATALYSTS AND METHODS FOR POLYMER SYNTHESIS NOVOMER, INC. (US) 2011-06-23 US disclosed
US-20110111044-A1 NANOPARTICLE COMPOSITIONS FOR NUCLEIC ACIDS DELIVERY SYSTEM ENZON PHARMACEUTICALS, INC. (US) 2011-05-12 US disclosed
US-7872145-B2 7,11-dihydroxy-17-(2-hydroxyethyl)-8,8,10,12-tetramethyl-3-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)-4-oxa-17-azabicyclo[14.1.0]heptadecane-5,9-dione; anticarcinogenic agent; antiproliferative agent; low toxicity ( side effects reduction) Bristol-Mysers Squibb Company (US) 2011-01-18 US disclosed
US-7858807-B2 Method for producing 1-substituted-5-acylimidazole compound UBE INDUSTRIES, LTD. (JP) 2010-12-28 US disclosed
US-20100324302-A1 PROCESSES FOR MAKING EPOTHILONE COMPOUNDS AND ANALOGS BRISTOL-MYERS SQUIBB COMPANY 2010-12-23 US disclosed
US-20090306399-A1 METHOD FOR PRODUCING 1-SUBSTITUTED-5-ACYLIMIDAZOLE COMPOUND UBE INDUSTRIES, LTD. (JP) 2009-12-10 US disclosed
EP-1927590-A1 METHOD FOR PRODUCING 1-SUBSTITUTED-5-ACYLIMIDAZOLE COMPOUND Ube Industries, Ltd. (JP) 2008-06-04 EP disclosed
US-20070276018-A1 AZIRIDINYL-EPOTHILONE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-29 US disclosed
US-7300921-B2 Polyene polyketides and methods of production ECOPIA BIOSCIENCES, INC. (CA) 2007-11-27 US disclosed